Tech Company Financing Transactions
Lux Biosciences Funding Round
Private investors participated in a $5 million funding round for Lux Biosciences. The round was announced on 12/20/2010.
Transaction Overview
Company Name
Announced On
12/20/2010
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. Amounts included options, warrants or other rights to acquire other securities. SEC regulatory filing.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
3 Second Street 14th Floor
Jersey City, NJ 07302
USA
Jersey City, NJ 07302
USA
Phone
Website
Email Address
Overview
Lux Biosciences is a biotechnology company specialized in the field of ophthalmic diseases. We are developing medications to treat the underlying causes of these diseases and alleviate their symptoms. Ultimately, we strive to improve or preserve the eyesight of patients with these diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dean Mitchell
Chief Medical Officer
Eddy Anglade
Chief Operating Officer
Clarke Atwell
Browse more venture capital transactions:
Prev: 12/20/2010: CaseNET venture capital transaction
Next: 12/20/2010: Capricor Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs